Frontiers in Metastatic Breast Cancer

Posted On 2023-04-04 14:12:08
Frontiers in Metastatic Breast Cancer
Editors: Xiaojia Wang , Lorenzo Rossi , Stephen J. Luen

Publisher: AME Publishing Company; 1st edition (2021)
ISBN: 978-988-74593-5-4
Hardcover: 366 pages
Language: English
Available at:

This book is an organic, multidisciplinary and comprehensive collection of articles aimed at clarifying the most important and the most innovative aspects in the local or systemic treatments of metastatic breast cancer. They are divided into seven sections: in the first section there is an interesting overview on metastatic breast cancer which mainly evaluates emerging new biomarkers and rare sites of breast cancer metastasis. There are also three sections dedicated to chemotherapy, endocrine therapy and target therapy (including immunotherapy). Local treatment strategies (radiotherapy, surgery) are also considered. There is also a specific section for the treatment of metastases in “special” sites such as brain and bone. Finally, there is a section dedicated to palliative care and the general management of this heterogeneous group of pathologies. This special book provides a set of research papers of high quality useful in order to optimize the clinical management of metastatic breast cancer by a multidisciplinary approach thanks to the contribution of important international authors.

HONORARY EDITORS

Zefei Jiang Department of Breast Cancer, The Fifth Medical Center of PLA General Hospital, Beijing, China
Gianluca Franceschini Multidisciplinary Breast Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

EDITORS

Xiaojia Wang Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China
Lorenzo Rossi Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland
Stephen J. Luen Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

ASSOCIATE EDITORS

Zhanhong Chen Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China
Xiying Shao Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital; Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China